Two researches at Texas A&M University have developed a diagnostic software for monitoring electrical equipment to prevent outages and even wildfires. Getty Images

The threat of wildfires is on most people's minds as Australia suffers from devastating, uncontrollable fires in its southeastern region. While Australia's fires are alleged to be caused by natural occurrences, some, like the California wildfires of late 2019, are caused by electrical malfunctions and sparks

Engineers at Texas A&M University have found a solution for preventing these electricity-caused wildfires — and the subsequently caused electrical outages — with their diagnostic software called Distribution Fault Anticipation, or DFA. The software can interpret variations in the electrical current on utility circuits — usually caused by issues with the equipment — that can cause outages or spark fires.

A Texas A&M research team — spearheaded by B. Don Russell, professor of electrical and computer engineering, and research professor Carl L. Benner — is behind the DFA software.

The technology has been tested at over a dozen utilities in Texas over the past six years, according to a news release, and now two Californian utility companies — Pacific Gas & Electric and Southern California Edison — will be testing DFA. In 2018, a state law from the California Public Utilities Commission began requiring utilities to submit Wildfire Mitigation Plans, per the release.

Up next: The researchers are preparing to test the software in Australia and New Zealand.

DFA's specific algorithms are based on and refined through 15 years of research. Russell and Benner liken DFA to the diagnostic tools cars use, and, comparatively, the utilities industry is way behind the times.

"Utility systems operate today like my 1950s Chevy," Russell says in the release. "They have some fuses and breakers and things, but they really don't have anything diagnostic. They don't have that computer under the hood telling them what's about to go wrong."

B. Don Russell, professor of electrical and computer engineering, led the research at A&M. Photo via A&M

Normal wear and tear on electrical equipment is inevitable, but it's hard for inspectors to visually see this damage. Until this DFA software, utilities had no choice but to react to failures or outages, rather than put money into prevention. The software allows for these companies to better see what could potentially cause issues. And, now with the ability to factor in dry conditions and weather, the software can even predict potential wildfires.

"Power is being turned off with nothing known to be wrong with a given circuit," Russell says in the release. "Utilities need a crystal ball, something telling them which circuit is going to start a fire tomorrow because it is already unhealthy. We are kind of that crystal ball."

DFA has the potential to prevent outages and devastation caused by wildfires, and it also is a huge economic solution for utilities companies — especially the ones reeling from the recent fires in California.

Pacific Gas & Electric, which is testing nine DFA devices, is the state's largest utility company and recently filed for bankruptcy due to a near $100 billion required from settlements following recent fires. By comparison, a DFA device costs only $15,000, according to the release.

"DFA is a new tool, allowing utilities to transform their operating procedures to find and fix problems before catastrophic failures." Russell says in the release. "Utilities operators need real time situational awareness of the health of their circuits…..DFA does that."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”